Variant Summary
- Also known as
- ARG132
- HGVS
- NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G
- Variant Type(s)
- protein_altering_variant
- Evidence Items
- 11
Evidence Level Distribution
Level A: 1Level B: 9Level D: 1
Evidence Items
Showing CIViC evidence rows where gene = IDH1 and variant = R132.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Cholangiocarcinoma | Ivosidenib | 5 |
| B | Prognostic | Supports | Better Outcome | Glioblastoma | 5 | |
| B | Prognostic | Supports | Better Outcome | Malignant Astrocytoma | 5 | |
| B | Prognostic | Supports | Poor Outcome | Myelodysplastic Syndrome | 4 | |
| D | Predictive | Supports | Sensitivity/Response | Intrahepatic Cholangiocarcinoma | Dasatinib | 4 |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 3 | ||
| B | Prognostic | Supports | Better Outcome | Malignant Astrocytoma | 3 | |
| B | Prognostic | Supports | Better Outcome | Glioblastoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | High Grade Glioma | Sunitinib,Bevacizumab | 2 |
| B | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | 2 | |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 2 |